What is it about?
This study of a cohort of patients diagnosed with DLBCL shows that patients with minimal involvement per FC, of more than 1% of the total WBC, may reflect an intermediate risk category, with emphasis on time to progression.
Featured Image
Why is it important?
A new and more accurate way to know the prognosis of diffuse large B cell lymphoma through the use of flow cytometry
Perspectives
The aim of this study was to ascertain whether minimal involvement of the bone marrow (BM), evident only in Flow cytometry, has prognostic and clinical characteristics similar to those of a positive biopsy, or rather to those patients without BM disease involvement. In our cohort, the time to progression (TTP) and overall survival (OS) differed between the groups, and flow cytometry BM involvement was found to be an independent risk factor for disease progression, while the IPI (which includes BM involvement per biopsy as stage 4 disease) was associated with lower OS.
MD/PhD ZVI HOWARD PERRY
McGill University
Read the Original
This page is a summary of: The prognostic significance of bone marrow involvement in diffuse large B cell lymphoma according to the flow cytometry, Leukemia & Lymphoma, April 2019, Taylor & Francis,
DOI: 10.1080/10428194.2019.1587755.
You can read the full text:
Contributors
The following have contributed to this page
